Addison Capital Co Sells 432 Shares of Johnson & Johnson (NYSE:JNJ)

Addison Capital Co lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.9% in the fourth quarter, Holdings Channel.com reports. The fund owned 47,965 shares of the company’s stock after selling 432 shares during the quarter. Johnson & Johnson comprises 2.8% of Addison Capital Co’s holdings, making the stock its 9th largest holding. Addison Capital Co’s holdings in Johnson & Johnson were worth $6,937,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in the stock. IFS Advisors LLC boosted its stake in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares during the last quarter. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson in the fourth quarter worth $32,000. RPg Family Wealth Advisory LLC bought a new position in shares of Johnson & Johnson during the third quarter worth $35,000. Activest Wealth Management acquired a new position in shares of Johnson & Johnson in the 3rd quarter valued at $40,000. Finally, NewSquare Capital LLC increased its position in shares of Johnson & Johnson by 145.8% in the 4th quarter. NewSquare Capital LLC now owns 290 shares of the company’s stock valued at $42,000 after buying an additional 172 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on JNJ. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Morgan Stanley lowered their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Wells Fargo & Company cut their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a research report on Monday, March 10th. Finally, Barclays boosted their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $171.33.

Insider Buying and Selling

In other news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Johnson & Johnson Trading Down 0.0 %

NYSE JNJ opened at $162.94 on Monday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a 50 day moving average of $154.98 and a 200-day moving average of $156.27. The company has a market cap of $392.29 billion, a PE ratio of 24.50, a PEG ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter last year, the firm posted $2.29 EPS. The company’s quarterly revenue was up 5.3% on a year-over-year basis. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.04%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.